Enanta Pharmaceuticals, Inc. reported $65M of revenue over the trailing twelve months, +0.70% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $65M (to Q3 2026). Net income: −$63M, trailing twelve months to Q3 2026. Free cash flow: −$37M, trailing twelve months to Q3 2026. Operating margin: −93%, trailing twelve months to Q3 2026.

ENTAEnanta Pharmaceuticals, Inc.

Healthcare

$12.10+9.2% 1Y

$12.10

$10.4752 weeks$16.85

ENTA as reported

Enanta Pharmaceuticals, Inc. reported $65M of revenue over the trailing twelve months, +0.70% on the year before. 9 reported series are charted on this page, each one as filed.

$65M

Revenue, trailing twelve months · to Q3 2026 · +0.70% against the twelve months before

Net income: −$63M
Net income · −31% year on year · trailing twelve months to Q3 2026
Free cash flow: −$37M
Free cash flow · −15% year on year · trailing twelve months to Q3 2026
Operating margin: −93%
Operating margin · trailing twelve months to Q3 2026

Details›

Every series Ryufin has for ENTA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$65M	+0.70%	Q3 2026
Net income	−$63M	−31%	Q3 2026
EPS	−$2.42	−44%	Q3 2026
Operating margin	−93%	n/a	Q3 2026
Net margin	−100%	n/a	Q3 2026
ROE	−75%	n/a	Q3 2026
ROA	−23%	n/a	Q3 2026
Free cash flow	−$37M	−15%	Q3 2026
P/E	34.6	n/a	Q2 2020 · 25 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.